The median survival for estrogen receptor (ER)-positive/HER2-positive BC improved by 2.5 years, that for ER-negative/HER2-positive BC improved by 1.6 years, and that for ER-negative/HER2-negative BC improved by 0.5 years. The gene discussed is ERBB2; the disease is breast cancer.